FDA grants new indication for Novartis’ Afinitor

SILVER SPRING, Md. — The Food and Drug Administration has granted Novartis’ Afinitor (everolimus) tablets a new indication after giving it a priority review designation. The drug can now be prescribed to treat adults with unresectable, locally advanced of metastatic progressive, well-differentiated nonfunctional neuroendocrine tumors (NET) with lung or gastrointestinal origin.

 

“Afinitor is the first treatment approved for progressive, nonfunctional NET of lung origin, and one of very few options available for progressive, nonfunctional GI NET, representing a shift in the treatment paradigm for these cancers," Novartis Oncology president Bruno Strigini said. “We are proud of our Afinitor development program, which has translated to meaningful benefits for patients with several different cancers and rare diseases.”